Real-World Outcomes of Antiangiogenic Therapy in Patients With Wet Age-Related Macular Degeneration

Age-related macular degeneration (AMD) is one of the leading causes of irreversible blindness in developing countries. The treatment of choice is intravitreal antiangiogenic therapy. However, there are discrepancies between outcomes observed in real-world clinical practice and those reported in clinical trials such as RIVAL, MARINA, ANCHOR, and PrONTO.  Objective: The objective of this study was to explore real-world outcomes in visual acuity (VA) and central macular thickness (CMT) in patients with wet AMD treated with antiangiogenic therapy.  Methods: This was an ambispective, observational, and analytical study. A total of 110 patients (132 eyes) diagnosed with wet AMD were included. All had complete clinical records, optical coherence tomography reports, and VA data from January 2017 to June 2020.  Results: More than 80% of the eyes showed improvement in VA post-loading dose, along with a statistically significant reduction in CMT. The number of antiangiogenic injections ranged from 3 to 33, with an average follow-up of 20.8±12.5 months.  Conclusion: Treatment received in real-world clinical practice differs from the protocols established in multicenter trials, particularly regarding injection frequency. Despite these variations, a positive trend was observed in both visual improvement and CMT reduction at the end of follow-up.